IMMUNOVANT INC (IMVT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:IMVT • US45258J1025

25.8 USD
-0.28 (-1.07%)
At close: Feb 3, 2026
25.8 USD
0 (0%)
After Hours: 2/3/2026, 8:24:44 PM
Fundamental Rating

3

IMVT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. IMVT has a great financial health rating, but its profitability evaluates not so good. IMVT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year IMVT has reported negative net income.
  • In the past year IMVT has reported a negative cash flow from operations.
  • IMVT had negative earnings in each of the past 5 years.
  • IMVT had a negative operating cash flow in each of the past 5 years.
IMVT Yearly Net Income VS EBIT VS OCF VS FCFIMVT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • With a Return On Assets value of -79.69%, IMVT is not doing good in the industry: 67.37% of the companies in the same industry are doing better.
  • Looking at the Return On Equity, with a value of -89.39%, IMVT is in line with its industry, outperforming 49.05% of the companies in the same industry.
Industry RankSector Rank
ROA -79.69%
ROE -89.39%
ROIC N/A
ROA(3y)-48.07%
ROA(5y)-40.13%
ROE(3y)-52.89%
ROE(5y)-43.9%
ROIC(3y)N/A
ROIC(5y)N/A
IMVT Yearly ROA, ROE, ROICIMVT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • IMVT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IMVT Yearly Profit, Operating, Gross MarginsIMVT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

8

2. Health

2.1 Basic Checks

  • The number of shares outstanding for IMVT has been increased compared to 1 year ago.
  • The number of shares outstanding for IMVT has been increased compared to 5 years ago.
  • IMVT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IMVT Yearly Shares OutstandingIMVT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
IMVT Yearly Total Debt VS Total AssetsIMVT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 37.62 indicates that IMVT is not in any danger for bankruptcy at the moment.
  • IMVT's Altman-Z score of 37.62 is amongst the best of the industry. IMVT outperforms 94.47% of its industry peers.
  • There is no outstanding debt for IMVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 37.62
ROIC/WACCN/A
WACCN/A
IMVT Yearly LT Debt VS Equity VS FCFIMVT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 9.07 indicates that IMVT has no problem at all paying its short term obligations.
  • IMVT has a Current ratio of 9.07. This is in the better half of the industry: IMVT outperforms 79.20% of its industry peers.
  • A Quick Ratio of 9.07 indicates that IMVT has no problem at all paying its short term obligations.
  • IMVT has a Quick ratio of 9.07. This is in the better half of the industry: IMVT outperforms 79.20% of its industry peers.
Industry RankSector Rank
Current Ratio 9.07
Quick Ratio 9.07
IMVT Yearly Current Assets VS Current LiabilitesIMVT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

1

3. Growth

3.1 Past

  • The earnings per share for IMVT have decreased strongly by -27.93% in the last year.
EPS 1Y (TTM)-27.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, IMVT will show a very strong growth in Earnings Per Share. The EPS will grow by 23.76% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-8.6%
EPS Next 2Y-4.86%
EPS Next 3Y2.54%
EPS Next 5Y23.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
IMVT Yearly Revenue VS EstimatesIMVT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 1B 2B 3B 4B
IMVT Yearly EPS VS EstimatesIMVT Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10 15 20 25

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • IMVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IMVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IMVT Price Earnings VS Forward Price EarningsIMVT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IMVT Per share dataIMVT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.86%
EPS Next 3Y2.54%

More info and screens

0

5. Dividend

5.1 Amount

  • IMVT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

IMMUNOVANT INC

NASDAQ:IMVT (2/3/2026, 8:24:44 PM)

After market: 25.8 0 (0%)

25.8

-0.28 (-1.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)02-06
Inst Owners47.26%
Inst Owner Change0.02%
Ins Owners1.29%
Ins Owner Change14%
Market Cap4.52B
Revenue(TTM)N/A
Net Income(TTM)-464.56M
Analysts81.74
Price Target40.26 (56.05%)
Short Float %22.91%
Short Ratio10.36
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.9%
Min EPS beat(2)-7.99%
Max EPS beat(2)0.2%
EPS beat(4)3
Avg EPS beat(4)1.3%
Min EPS beat(4)-7.99%
Max EPS beat(4)12.44%
EPS beat(8)4
Avg EPS beat(8)-3.65%
EPS beat(12)5
Avg EPS beat(12)-6.43%
EPS beat(16)6
Avg EPS beat(16)-5.09%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.94%
PT rev (3m)4.28%
EPS NQ rev (1m)0.15%
EPS NQ rev (3m)1.41%
EPS NY rev (1m)0%
EPS NY rev (3m)0.51%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.7
P/tB 8.7
EV/EBITDA N/A
EPS(TTM)-2.84
EYN/A
EPS(NY)-3.01
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.46
OCFYN/A
SpS0
BVpS2.96
TBVpS2.97
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -79.69%
ROE -89.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.07%
ROA(5y)-40.13%
ROE(3y)-52.89%
ROE(5y)-43.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 90.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.07
Quick Ratio 9.07
Altman-Z 37.62
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)154.15%
Cap/Depr(5y)190.95%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-27.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.35%
EPS Next Y-8.6%
EPS Next 2Y-4.86%
EPS Next 3Y2.54%
EPS Next 5Y23.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-38.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-20.74%
EBIT Next 3Y-7.34%
EBIT Next 5YN/A
FCF growth 1Y-105.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.52%
OCF growth 3YN/A
OCF growth 5YN/A

IMMUNOVANT INC / IMVT FAQ

Can you provide the ChartMill fundamental rating for IMMUNOVANT INC?

ChartMill assigns a fundamental rating of 3 / 10 to IMVT.


What is the valuation status of IMMUNOVANT INC (IMVT) stock?

ChartMill assigns a valuation rating of 0 / 10 to IMMUNOVANT INC (IMVT). This can be considered as Overvalued.


What is the profitability of IMVT stock?

IMMUNOVANT INC (IMVT) has a profitability rating of 0 / 10.


What is the expected EPS growth for IMMUNOVANT INC (IMVT) stock?

The Earnings per Share (EPS) of IMMUNOVANT INC (IMVT) is expected to decline by -8.6% in the next year.